Policy Number: AHS – M2139 – Molecular Analysis for Gliomas	Policy Revision Date: 02/01/2026 Initial Policy Effective Date: 12/01/2024

POLICY DESCRIPTION | RELATED POLICIES | INDICATIONS AND/OR LIMITATIONS OF COVERAGE | TABLE OF TERMINOLOGY | SCIENTIFIC BACKGROUND | GUIDELINES AND RECOMMENDATIONS | APPLICABLE STATE AND FEDERAL REGULATIONS | APPLICABLE CPT/HCPCS PROCEDURE CODES | EVIDENCE-BASED SCIENTIFIC REFERENCES | REVISION HISTORY

I. Policy Description

Glioma refers to tumors resulting from metaplastic transformation of glial cells of the central nervous system. Tumors have historically been classified by the retained histologic features of the three types of glial cells: astrocytes, oligodendrocytes, and ependymal cells. Tumors of each type can vary widely in aggressiveness, response to treatment, and prognosis.[1]

Molecular genetic features were added to histopathologic appearance in the current WHO classification to yield more biologically homogeneous and narrowly defined diagnostic entities for greater diagnostic accuracy, improved patient management, more accurate determinations of prognosis, and better treatment response.[2,3]

II. Related Policies

Policy Number	Policy Title
N/A	Not Applicable

III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

1) For the prognosis of gliomas, the following tests **MEET COVERAGE CRITERIA:**
   a) Array-based genomic copy number testing or fluorescence in situ hybridization (FISH) for the co-deletion of 1p and 19q.
   b) *ATRX* mutation testing via gene sequencing **or** loss of ATRX protein expression via immunohistochemistry.
   c) *BRAF* fusion and mutation testing, including *BRAF* V600E common variant.
   d) *IDH1* and *IDH2* testing.
   e) *MGMT* promoter methylation testing.
   f) *TERT* promotor mutation testing.

2) For the prognosis of diffuse midline gliomas, the following tests **MEET COVERAGE CRITERIA:**
   a) *H3-3A* and *HIST1H3B* gene sequencing.
   b) *H3-3A* mutation testing by immunohistochemistry using an H3-3A K27M histone antibody.

3) For the prognosis of ependymomas, *ZFTA* fusion testing using either RNA sequencing analysis (RNA-Seq) or FISH **MEETS COVERAGE CRITERIA**.

4) *ATRX* mutation co-testing using **both** immunohistochemistry and gene sequencing **DOES NOT MEET COVERAGE CRITERIA**.

NOTES:

Note: For two or more gene tests being run on the same platform, please refer to AHS-R2162 Reimbursement Policy.

IV. Table of Terminology

Term	Definition
AG	Anaplastic glioma
ATRX	*Alpha-Thalassemia/Mental Retardation Syndrome X-Linked* gene
BRAF	*B-Raf proto-oncogene*
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers For Medicare and Medicaid
CNA	Copy number alterations
CNS	Central nervous system
CSF	Cerebrospinal fluid
ddPCR	Digital droplet polymerase chain reaction
DIPG	Diffuse intrinsic pontine gliomas
EANO	European Association of Neuro-Oncology
ELISA	Enzyme-linked immunoassay
ESMO	European Society for Medical Oncology
FISH	Fluorescence in situ hybridization
H3-3A	*H3.3 histone A* gene
H3F3A	Previous gene name of *H3.3 histone A*
H3FA	*H3 clustered histone 1* gene
IDH1	*Isocitrate Dehydrogenase 1* gene
IDH2	*Isocitrate Dehydrogenase 2* gene
LDTs	Laboratory-developed tests
MGMT	*O-6-Methylguanine-Dna Methyltransferase* gene
NCCN	National Comprehensive Cancer Network
NICE	National Institute for Health and Care Excellence
NFkB	Nuclear factor kappa B

NGS	Next-generation sequencing
NICE	National Institute for Health and Care Excellence
PCR	Polymerase chain reaction
PFA	Posterior fossa ependymoma group A
PFB	Posterior fossa ependymoma group B
RELA	*RELA proto-oncogene, NF-kB subunit*
RNA-Seq	Ribonucleic acid sequencing analysis
SNVs	Single nucleotide variants
sPD-L1	Soluble programmed cell death ligand 1
TERT	*Telomerase reverse transcriptase*
TMB	Tumor mutational burden
TP53	*Tumor protein 53*
WHO	World Health Organization
YAP1	*Yes1 associated transcriptional regulator* gene
ZFTA	*Zinc finger translocation associated* gene

V. Scientific Background

According to the American Cancer Society, an estimated 24,820 individuals in the United States were diagnosed with malignant tumors of the brain and spinal cord in 2025. Additionally, The American Cancer Society reported that there was an estimated 18,330 deaths from brain and spinal cord tumors in 2025.[4]

Studies over the past two decades have clarified the genetic basis of tumorigenesis in the common, and some rarer, brain tumor entities,[2] and identified clinically relevant molecular genetic characterizations that complement standard histologic analysis providing additional diagnostic and prognostic information to improve diagnostic accuracy, influence treatment selection, and improve survival. Molecular and/or genetic characterization do not replace standard histologic assessment, but rather serve as a complimentary approach that often enhances treatment selection.[5]

Isocitrate dehydrogenase (IDH1/2) mutations

Metabolic enzymes, IDH one and two, oxidize isocitrate to alpha-ketoglutarate, and are important in the mitigation of cellular oxidative damage.[6] Mutations in genes encoding these enzymes leads to the aberrant production of D-2 hydroxyglutarate,[7] an oncometabolite that causes epigenetic modifications in affected cells.[6]

The *IDH* mutations are a defining feature of WHO grade II and III astrocytomas and oligodendrogliomas.[2] Their presence distinguishes lower grade gliomas from primary glioblastomas, which are *IDH* wild type. *IDH* mutations are commonly associated with O-6-methylguanine-DNA methyltransferase (*MGMT*) promoter methylation and are also associated with a relatively favorable prognosis.[8,9]

O-6-methylguanine-DNA methyltransferase (MGMT) methylation

The DNA repair enzyme, MGMT, reverses the DNA damage caused by alkylating agents, resulting in tumor resistance to temozolomide and nitrosourea-based chemotherapy. Methylation of the *MGMT* promoter silences *MGMT,* making the tumor more sensitive to treatment with alkylating agents.[10,11]

The *MGMT* promoter methylation is strongly associated with *IDH* mutation and genome-wide epigenetic change;[8] it is also associated with longer survival in patients with glioblastoma who receive alkylating agents.[12,13] *MGMT* promoter methylation is particularly useful in treatment decisions for elderly patients with high grade gliomas.[14-16]

Codeletion of chromosomes 1p and 19q

The codeletion of 1p and 19q represents an unbalanced translocation (1;19) (q10;p10) leading to the whole arm deletion of chromosome 1p and chromosome 19q.[17] Codeletion of 1p and 19q is a defining feature of oligodendroglial tumors, is strongly associated with oligodendroglial histology, and helps to confirm the oligodendroglial character of tumors with equivocal or mixed histologic features.[8,9,18] Combined loss involving chromosomes 1p and 19q is significantly associated with both favorable therapeutic response and longer recurrence-free survival after chemotherapy.[19]

Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) mutations

Mutations in the chromatin regulator gene, *ATRX*, enable alternative lengthening of telomeres.[20] ATRX is a switch/sucrose helicase that assists with H3.3 chromatin deposition in telomeric regions. Disruption of this gene leads to the alternative lengthening of telomeres stated above and is thought to represent an early event in gliomagenesis.[21]

The *ATRX* mutations in glioma are strongly associated with *IDH* and *TP53* mutations and are nearly always mutually exclusive with 1p19q codeletion.[22] ATRX deficiency, coupled with *IDH* mutation, is typical of astrocytoma.[9]

Tumor protein 53 (TP53) mutation

Tumor protein 53 is essential for regulating cell division and preventing tumor formation.[23] Missense mutations in the *TP53* gene are present in the clear majority of IDH-mutant astrocytomas.[9] Immunopositivity for mutant p53 is not entirely sensitive or specific for a *TP53* mutation, however, and loss of *ATRX* expression may be a more reliable marker of astrocytic differentiation.[1]

Telomerase reverse transcriptase (TERT) mutations

Telomerase reverse transcriptase encodes the catalytic active site of telomerase, the enzyme responsible for maintaining telomere length in dividing cells. *TERT* mutations in the noncoding promoter region cause increased expression of the TERT protein and are one of the major mechanisms of telomerase activation in gliomas.[24] *TERT* mutations are strongly associated with 1p19q codeletion and are found in most glioblastomas. A *TERT* mutation in combination with an *IDH* mutation and 1p19q codeletion is characteristic of oligodendroglioma. The absence of a *TERT* mutation, coupled with an *IDH* mutation, designates astrocytoma.[8] In terms of survival, mutation in the *TERT* promoter is generally unfavorable in the absence of *IDH* mutation and favorable in the presence of *IDH* mutation and 1p/19q

codeletion. *TERT* promoter mutation is associated with an older age of the patient at presentation, regardless of whether *IDH* mutation is present.[8]

Histone (H3FA) mutations

A lysine to methionine substitution in the *H3F3A* gene (*H3K27M*) is the most common histone mutation in brain tumors and inhibits the trimethylation of H3.3 histone,[25] arresting cells in a primitive state refractory to differentiation induction.[26] *G34R/G34V* mutations in the *H3F3A* gene are more common in cortical gliomas in children.[27] *H3FA* mutations can be useful in the diagnosis of infiltrative glioma.[25] The *H3K27M* mutation is an adverse prognostic marker in children and adults.[28] The *G34* mutation does not appear to have any prognostic significance once the diagnosis of a glioblastoma has been established.[25]

A similar mutation to *H3K27M* may also occur in the *HIST1H3B/C* gene, which encodes the histone H3.1 variant. However, the mutation at *HIST1H3B/C* is about one third as common as *H3F3A* and often confers a better prognosis than its *H3F3A* counterpart.[1]

B-Raf proto-oncogene (BRAF) mutations

The serine-threonine protein kinase, BRAF, is involved in cell survival, proliferation, and differentiation.[29] Activating mutations in *BRAF*, most often V600E, have been discovered in most pediatric and some adult gliomas,[30,31] including approximately 80% of pleomorphic xanthoastrocytomas, 20% of gangliogliomas, 10% of pilocytic astrocytomas, and occasionally diffuse gliomas.[32] Tandem duplication of chromosome 7q34 resulting in an activating fusion of the *BRAF* and *KIAA1549* genes occur in 60-80% of pilocytic astrocytoma.[33]

The presence of a *BRAF* fusion is reliable evidence that the tumor is a pilocytic astrocytoma and predicts a better clinical outcome.[34] A *BRAF* mutation is more complicated, as it can occur in a variety of tumors and requires integration with histology. Tumors with *BRAF* mutations may respond to BRAF inhibitors; however, in pediatric gliomas, *BRAF* V600E indicates poor prognosis when treated with current adjuvant therapy, especially in combination with a *CDKN2A* mutation.[35]

v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA, p65, NFKB3) fusion

Fusion between the *C11orf95* and *RELA* genes defines approximately 70 percent of all childhood supratentorial ependymomas.[1] These fusions are associated with increased NF-kappa-B (NFkB) signaling and poor outcome.[36] Normally, NFkB is an inactive transcription factor in the cytoplasm. When its inhibitor degrades, it activates transcription of certain genes, *RELA* among them.[37] New research supports the hypothesis that the status of *RELA* fusion and p53 overexpression are significantly associated with the prognosis of supratentorial extraventricular ependymomas.[38]

New Tests

Assessment of gliomas is incredibly difficult, and new methods of molecular analyses for gliomas are consistently being developed. For example, Miller, et al. (2019) devised a liquid-biopsy based method to evaluate cerebrospinal fluid from 42 (of 85) patients. The genomic profile developed from the cerebrospinal fluid (CSF) samples closely matched established profiles, such as the characteristic 1p/19q codeletion and *IDH1/2* mutations. The authors stated that the ability to monitor the glioma genome in real time could be useful in management of this condition.[39] Other researchers report that "A cerebrospinal fluid ct-DNA liquid biopsy approach may virtually support all the stages of glioma

management, from facilitating molecular diagnosis when surgery is not feasible, to monitoring tumor response, identifying early recurrence, tracking longitudinal genomic evolution, providing a new molecular characterization at recurrence and allowing patient selection for targeted therapies."[40]

Clinical Utility and Validity

Nikiforova, et al. (2016) validated GlioSeq, a commercial next generation sequencing (NGS) panel of 30 genes, in 54 patients with CNS tumors against fluorescence in-situ hybridization (FISH), Sanger sequencing, and reverse transcription polymerase chain reaction (PCR). GlioSeq correctly identified 71/71 (100%) genetic alterations known to be present by conventional techniques. The assay sensitivity was three to five percent for mutant alleles of single nucleotide variants (SNVs), and one to five percent for gene fusions. Likewise, Zacher, et al. (2017) developed an NGS panel of 20 genes that allowed for molecular classification of 121 gliomas. The researchers conclude that gene panel NGS is a promising diagnostic technique that may facilitate integrated histological and molecular glioma classification.

Taeeun, et al. (2024) preformed a targeted panel-based NGS analysis on formalin-fixed and paraffin-embedded nucleic acids extracted from a total of 147 glioma patients. These studies included assessment of IDH1 R132H, ATRX, BRAF V600E, and H3K27M expression through IHC, as well as identification of *IDH1, IDH2*, and *TERT*p mutations using Sanger sequencing. Additionally, 1p/19q codeletion was assessed using FISH. The routine use of multigene NGS analysis, is an effective way to classify gliomas and allows for the identification of a greater number of genetic alterations and rare genomic events, leading to more treatment options for glioma patients. Consequently, NGS analysis is required for diagnosis, prognosis, eligibility for clinical trial enrollment, and treatment decisions in patients with glioma.[43]

Ramkissoon, et al. (2017) used OncoPanel and OncoCopy to identify targetable alterations in tumors for the establishment of best practices in routine clinical pediatric oncology. They analyzed 117 samples by OncoPanel and 146 by OncoCopy; further, 60 tumors were subjected to both methodologies. OncoPanel revealed clinically relevant alterations in 56% of patients (44 cancer mutations and 20 rearrangements), including *BRAF* alterations that directed the use of targeted inhibitors. Rearrangements in *MYB-QKI, MYBL1, BRAF*, and *FGFR1* were also detected. Furthermore, while copy number profiles differed across histologies, the combined use of OncoPanel and OncoCopy identified subgroup-specific alterations in 89% (17/19) of medulloblastomas.

Ryall, et al. (2016) evaluated the prognostic impact of H3K27M and MAPK pathway aberrations in 64 gliomas (44 low grade, 22 high grade). Tumors are designated as low-grade if the cells are well differentiated, are less aggressive overall, and suggest a better prognosis for the patient. Five low grade gliomas contained the *H3F3A/HIST1H3B K27M* (*H3K27M*) mutation, and 11 high grade gliomas contained the *H3K27M* mutation. Survival analysis evaluated the median survival at 9.12 years for wildtype H3 patients compared to 1.02 years for patients with the *H3K27M* mutation. MAPK pathway mutations (through *BRAF* or *FGFR1* mutation) were associated with long-term survival in absence of *H3K27M* mutations. Further, H3K27M status and high-grade histology were found to be the most significant independent predictors of poor overall survival with hazard ratios of 6.945 and 7.721 respectively. MAPK pathway activation was a predictor of "favourable patient outcome," but dependent on other factors.[45]

Houdova Megova, et al. (2017) evaluated the prognostic value of the *IDH1/2* mutation in glioblastomas. A total of 37 *IDH* mutations were examined and studied. The authors found that *IDH1* mutations were

positively associated with *MGMT* methylation (odds ratio [OR]: 3.08), 1p/19q co-loss (OR: 8.85), and negatively associated with *EGFR* amplification. IDH-mutant patients had an overall survival of 25 months compared to only nine months for IDH-wildtype gliomas.[46]

Johnson, et al. (2017) performed comprehensive genomic profiling of 282 pediatric gliomas: 157 high-grade and 125 low-grade. The investigators used a 315 gene panel and calculated the tumor mutational burden (TMB). In low grade gliomas, *BRAF* was the most frequent mutation found (48%), followed by *FGFR* missense (17.6%), *NF1* loss of function (8.8%), and *TP53* (5.6%). Rearrangements were found in 35% of low-grade gliomas. In high-grade gliomas, *TP53* was the most frequent mutation found (49%), followed by *H3F3A* (37.6%), *ATRX* (24.2%), *NF1* (22.2%), and *PDGFRA* (21.7%). *H3F3A* mutations were found to be the K28M variant. Approximately six percent of the high-grade gliomas were found have a TMB of >20 mutations/Mb ("hypermutated").[47]

Back, et al. (2020) studied the pattern of failure in anaplastic glioma (AG) patients with an *IDH1/2* mutation. A total of 156 patients participated in the study, with data collected from 2008 to 2014; the median follow-up time was 5.1 years. Of all 156 patients, 75% were found to have an *IDH1 or IDH2* mutation. The authors concluded that "patients with *IDH*-mutated AG have improved outcomes;" however, this population also had a greater number of distant relapses approximately two years after intensity-modulated radiation therapy compared to individuals with *IDH* wild type mutations.[48]

Ji, et al. (2021) studied the clinical utility of comprehensive genomic profiling to detect CNS tumors in children and young adults using the OncoKids next-generation sequencing panel, chromosomal microarray analysis, and germline testing. NGS was performed on 222 samples and CMA was performed on 146 of the 222 samples. The OncoKids NGS panel identified diagnostic biomarkers in 138/222 samples (62%), prognostic information in 49/222 cases (22%), and targetable genomic alterations in 41/222 samples (18%). Additionally, CMA revealed prognostic copy number alterations (CNA) in 101/146 cases (69%). Further, germline cancer predisposition testing was performed in 57 of 212 patients which identified 20 patients which a confirmed germline pathogenic/likely pathogenic variant of genes *TP53, NF1, SMARCB1, NF2, MSH6, PMS2*, and a patient with Klinefelter syndrome. Overall, the authors conclude that there is "significant clinical utility of integrating genomic profiling into routine clinical testing for pediatric and young adult patients with CNS tumors."[49]

Muralidharan, et al. (2021) studied the diagnostic utility of a novel digital droplet PCR (ddPCR) assay for detection of two TERT promoter mutations (*C228T* and *C250T*) and monitoring of gliomas. In comparison with the gold-standard tumor tissue-based detection of *TERT* mutations, the ddPCR assay had an overall sensitivity of 62.5% and a specificity of 90%. Longitudinal monitoring of five patients demonstrated that the peripheral *TERT* mutant allele frequency reflects the clinical course of the disease. *TERT* mutant alleles decreased after surgical intervention and pharmacotherapy but increased with tumor progression. The authors conclude that the ddPCR assay has feasibility in "detecting circulating cfDNA TERT promoter mutations in patients with glioma with clinically relevant sensitivity and specificity."[50]

Cabezas-Camarero, et al. (2021) studied the levels of soluble PD-L1 (sPD-L1) in patients with gliomas according to histologic grade and IDH mutation status, evaluating its predicted role and dynamic changes in sPD-L1. Plasma samples were obtained prior to and after radiotherapy/chemotherapy and were evaluated using ELISA. The authors compared 12 healthy controls with 57 patients with grade II to IV gliomas. They found that sPD-L1 levels were numerically higher in glioma patients as compared to the healthy control group. The authors found that elevated sPD-L1 levels pre- and post- treatment

associated with a worse prognosis in IDH-MUT gliomas. Dynamics of SPDL1 and other immune-biomarkers should still be explored in gliomas.[51]

Rios, et al. (2022) studied the health and economic impacts of using tumor molecular testing for guiding treatments for pediatric patients with low grade glioma. With their microsimulation for modeling health and cost outcomes for 100,000 simulated patients, they found that there was a statistically significant increase in life expectancy in those who received molecular testing for the BRAF mutation (40.08 vs 39.01 in those who did not receiving testing), and an increase of 0.38 quality-adjusted life-years (QALY) and $1384 reduction in costs due to likely avoidance of adverse events associated with radiation, like stroke and other neoplastic transformations. This study ultimately demonstrates that in this subset of patients, there could be long-term benefits in the treatment plans derived for childhood cancers, including the increased timely use of *BRAF*-specific biologic agents versus standard treatment with radiation.[52]

VI. Guidelines and Recommendations

National Comprehensive Cancer Network (NCCN)

The NCCN published Clinical Practice Guidelines in Oncology (2025) for Central Nervous System Cancers which recommend:

IDH1 and *IDH2* mutation

Recommendation: *IDH* mutation testing is required for the workup of glioma.

"The most common *IDH1* mutation (R132H) is reliably screened by mutation specific immunohistochemistry (IHC), which is recommended for all glioma patients. If the R132H immunostain result is negative, in the appropriate clinical context, sequencing of *IDH1* and *IDH2* is highly recommended to detect less common *IDH1* and *IDH2* mutations. Prior to age 55 years, sequencing of *IDH1* and *IDH2* is required if the R132H immunostain result is negative, or if the glioma is only grade 2 or 3 histologically. Standard sequencing methods include Sanger sequencing, pyrosequencing, and next-generation sequencing (NGS), and should be performed on formalin fixed, paraffin embedded tissue."[5]

MGMT promoter methylation

Recommendation: *MGMT* promoter methylation is an essential part of molecular diagnostics for all high-grade gliomas (grade 3 and 4). The NCCN also notes that "*MGMT* promoter methylation is strongly associated with *IDH* mutations and genome-wide epigenetic changes (G-CIMP phenotype)."[5]

"There are multiple ways to test for *MGMT* promoter methylation, including methylation-specific polymerase chain reaction (PCR), methylation-specific high-resolution melting, pyrosequencing, and droplet-digital PCR."[5]

"MGMT promoter methylation testing is particularly useful in treatment decisions for older adult patients with high-grade gliomas (grades 3–4)."[5]

Codeletion of 1p and 19q

Recommendation: 1p/19q testing is an essential part of molecular diagnostics for oligodendroglioma.

"The codeletion of 1p and 19q is detectable by array-based genomic copy number testing (preferable), or fluorescence in situ hybridization (FISH) … IDH-mutated gliomas that do NOT show loss of *ATRX* (for example, by IHC) should be strongly considered for 1p/19q testing, even if not clearly oligodendroglial by histology. Conversely, *IDH1* wild-type gliomas do not contain true whole-arm 1p/19q codeletion. Therefore, 1p/19q testing is unnecessary if a glioma is definitely *IDH*-wild-type, and a glioma should not be regarded as 1p19q-codeleted without an accompanying *IDH* mutation, regardless of the test results."[5]

ATRX mutation

"Recommendation: *ATRX* mutation testing is required for the workup of glioma."[5]

"*ATRX* mutations can be detected by IHC for wild-type *ATRX* (loss of wild type expression) and/or sequencing. ATRX mutations in glioma are strongly associated with *IDH* mutations and are nearly always mutually exclusive with 1p/19q codeletion. *ATRX* deficiency, coupled with IDH mutation and *TP53* mutation, is typical of astrocytoma. A lack of *ATRX* immunostaining in glioblastoma should trigger *IDH1/2* sequencing if *IDH1* R132H immunostaining is negative, due to frequent co-occurrence of *ATRX* and *IDH* mutations."[5]

TERT mutation

"Recommendation: *TERT* promoter mutation testing is recommended for the workup of gliomas."

"*TERT* promoter mutations are nearly always present in 1p/19q codeleted oligodendroglioma and are found in most glioblastomas. *TERT* promoter mutation, in combination with *IDH* mutation and 1p/19q codeletion, is characteristic of oligodendroglioma. Absence of *TERT* promoter mutation, coupled with the presence of mutant *IDH*, strongly suggests astrocytoma."[5]

H3F3A and *HIST1H3B* mutation

"Recommendation: *H3-3A* and *HIST1H3B* mutation testing is recommended in the appropriate clinical context."

"Diffuse midline gliomas should be screened for *H3-3A* mutations, specifically the H3K27M mutation. While sequencing is the gold standard, H3K27M-specific IHC, paired with H3K27 trimethylation immunostaining, is a reasonable alternative, especially when tissue is scarce. In these gliomas, H3K27M immunopositivity should be associated with loss of histone trimethylation immunostaining."

"Although a K27M histone antibody is available, it is not 100% specific and interpretation can be difficult for non-experts. Therefore, screening by *H3F3A* and *HIST1H3B* sequencing is a viable alternative and preferred approach, especially since it will also detect mutations in G34."[5]

"Diagnostic value: Histone mutations most commonly occur in pediatric midline gliomas (e.g., diffuse intrinsic pontine gliomas [DIPG]), although midline gliomas in adults can also contain histone modifications. Their presence can be considered solid evidence of an infiltrative glioma, which is often helpful in small biopsies of midline lesions that may not be fully diagnostic with light microscopy or do not fully resemble infiltrative gliomas."

"Prognostic value: The *K27M* gliomas typically do not have MGMT promoter methylation, and the mutation is an adverse prognostic marker in children and adults. The *G34* mutation does not appear to have any prognostic significance once the diagnosis of a glioblastoma has been established."[5]

BRAF mutation

"Recommendation: *BRAF* fusion and/or mutation testing is recommended in the appropriate clinical context."

"*BRAF* V600E is best detected by sequencing, and *BRAF* fusions can be detected with RNA-Seq or other PCR-based breakpoint methods that capture the main 16-9, 15-9, and 16-11 breakpoints between *BRAF* and its main fusion partner, *KIAA1549*. FISH is too unreliable to detect *BRAF* fusions."[5]

"The presence of a *BRAF* fusion is reliable evidence that the tumor is a [pilocytic astrocytoma], provided the histology is compatible. *BRAF* V600E is more complicated, as it can occur in a variety of tumors over all four WHO grades and requires integration with histology."

"Tumors with *BRAF* fusions tend to be indolent, with occasional recurrence but only rare progression to lethality. *BRAF* V600E tumors show a much greater range of outcomes and need to be considered in context with other mutations and clinicopathologic findings (e.g., CDKN2A/B deletion). *BRAF* V600E tumors may respond to BRAF inhibitors, such as vemurafenib, but comprehensive clinical trials are still ongoing."[5]

ZFTA fusion

"Testing for *ZFTA* and *YAP1* fusions is recommended in the appropriate clinical context. Ependymomas arising in the supratentorium often contain activating fusions of *ZFTA*. This leads to increased NF-kappa-B signaling and more aggressive behavior. This event is more common in children than in adults, and occurs only in the supratentorium, not the posterior fossa or spine."

"*ZFTA* fusion can be detected with RNA sequencing or a break-apart FISH probe set… Detection of *ZFTA* fusion is not required for the diagnosis of ependymoma, as this entity is still diagnosed by light microscopy."

"*ZFTA* fusion-positive ependymomas are now a distinct entity in the WHO classification of CNS tumors, as this subset of ependymomas tends to be far more aggressive than other supratentorial ependymomas, including those with *YAP1* fusions. PFA vs. PFB via methylation profiling is reasonable for posterior fossa ependymoma."[5]

Finally, the NCCN states there are no identified targeted agents with demonstrated efficacy in glioblastoma.[5]

Molecular classification of central nervous system cancers

"Genome-wide profiling of CpG methylation patterns has been shown to be a powerful way to classify brain tumors, including those with equivocal histologic features. While this testing method is rapidly gaining popularity, it cannot yet be regarded as a gold standard for diagnosis in all cases, because some tumors have methylation patterns that are so rare they have not yet been correlated with specific clinical/biological behavior."[5]

National Institute for Health and Care Excellence (NICE)

NICE recommends the following molecular markers for investigation of gliomas: *IDH1/2* mutations, *ATRX* mutations, 1p/19q co-deletion, histone H3.3 K27M, *BRAF* mutation, and *MGMT* promoter methylation (for prognosis). NICE also notes that testing *IDH* wild type gliomas for *TERT* promoter mutations may be considered.[53]

European Society for Medical Oncology (ESMO)

The ESMO has published clinical practice guidelines for the diagnosis, treatment, and follow-up of high-grade gliomas. They state that *MGMT* promoter methylation status, *IDH1/2* mutation status, and 1p/19q codeletions are "commonly determined" for assessment of gliomas.[54]

World Health Organization (WHO)

In 2016 and 2021, the WHO published guidelines on the classification of central nervous system tumors. These WHO guidelines, for the first time, incorporated molecular testing in the diagnosis of gliomas and medulloblastomas. The following key points were given by the WHO regarding molecular testing:

- "*IDH1* R132H, which accounts for approximately 90% of *IDH* mutations, can be detected immunohistochemically. If this testing is negative, sequencing of *IDH1* and *IDH2* is necessary to ensure that no other *IDH* mutations are present.
- Given the importance of *IDH* mutational status in the diagnosis or gliomas, at a minimum, it will be important that most institutions have the capacity to both stain tumor specimens for *IDH1* R132H by immunohistochemistry and, ideally, sequence those tumors that are negative for both *IDH1* and *IDH2* mutations."[55]
- "Because of the growing importance of molecular information in CNS tumor classification, diagnoses and diagnostic reports need to combine different data types into a single, 'integrated' diagnosis. To display the full range of diagnostic information available, the use of layered (or tiered) diagnostic reports is strongly encouraged. Such reports feature an integrated diagnosis at the top, followed by layers that display histological, molecular, and other key types of information."[3]
- Certain tumors (Diffuse astrocytoma, MYB- or MYBL1-altered; Angiocentric glioma; Polymorphous low-grade neuroepithelial tumor of the young; and Diffuse low-grade glioma, MAPK pathway-altered) "require molecular characterization and the integration of histopathological and molecular information in a tiered diagnostic format as molecular work-up helps to characterize the lesion as one type or the other."[3]
- For other tumors such as Myxopapillary ependymoma and Subependymoma, "although these can be identified with methylome studies, molecular classification does not provide added clinicopathological utility for these two tumors."[3]
- "Several molecular biomarkers are also associated with classification and grading of meningiomas, including SMARCE1 (clear cell subtype), BAP1 (rhabdoid and papillary subtypes), and KLF4/TRAF7 (secretory subtype) mutations, TERT promoter mutation and/or homozygous deletion of CDKN2A/B62, H3K27me3 loss of nuclear expression (potentially worse prognosis), and methylome profiling (prognostic subtyping)."[3]

European Association of Neuro-Oncology (EANO)

In 2021, the EANO published guidelines regarding diagnosis and management of adult patients with diffuse gliomas. The following recommendations were made on molecular testing:

- "Patients with relevant germline variants or suspected hereditary cancer syndromes should receive genetic counselling and might subsequently be referred for molecular genetic testing.
- Immunohistochemistry for mutant *IDH1* R132H protein and nuclear expression of *ATRX* should be performed routinely in the diagnostic assessment of diffuse gliomas.
- If immunohistochemistry for *IDH1* R132H is negative, sequencing of *IDH1* codon 132 and *IDH2* codon 172 should be conducted in all WHO grade 2 and 3 diffuse astrocytic and oligodendroglial gliomas as well as in all glioblastomas of patients aged < 55 years to enable integrated diagnoses according to the WHO classification and to guide treatment decisions.
- 1p/19q codeletion status should be determined in all *IDH*-mutant gliomas with retained nuclear expression of *ATRX*.
- *MGMT* promoter methylation status should be determined in glioblastoma, notably in elderly or frail patients, to aid in decision-making for the use of temozolomide.
- *CDKN2A/B* homozygous deletions should be explored in *IDH*-mutant astrocytomas.
- Combined chromosome seven gain and chromosome 10 loss (+7/–10 signature), *EGFR* amplification and *TERT* promoter mutation should be tested in *IDH*-wild-type diffuse gliomas lacking microvascular proliferation and necrosis as histological features of WHO grade 4 to allow for a diagnosis of *IDH*-wild-type glioblastoma."[56]

In addition, EANO published a table to summarize the molecular markers used for the diagnosis and management of gliomas.

Table 1: Molecular Markers for the Diagnosis and Management of Gliomas[56]

Molecular Marker	Diagnostic Roles
IDH1 R132 or IDH2 R172 mutation	"Distinguishes diffuse gliomas with IDH mutation from IDH-wild-type glioblastomas and other IDH-wild-type gliomas
1p/19q codeletion	Distinguishes oligodendroglioma, IDH-mutant and 1p/19q-codeleted from astrocytoma, IDH-mutant
Loss of nuclear ATRX	Loss of nuclear ATRX in an IDH-mutant glioma is diagnostic for astrocytic lineage tumours
Histone H3 K27M mutation	Defining molecular feature of diffuse midline glioma, H3 K27M-mutant
Histone H3.3 G34R/V mutation	Defining molecular feature of diffuse hemispheric glioma, H3.3 G34-mutant
MGMT promoter methylation	None, but is a predictive biomarker of benefit from alkylating chemotherapy in patients with IDH-wild-type glioblastoma
Homozygous deletion of CDKN2A/CDKN2B	A marker of poor outcome and WHO grade 4 disease in IDH-mutant astrocytomas
EGFR amplification	EGFR amplification occurs in ~40–50% of glioblastoma, IDH wild type Molecular marker of glioblastoma, IDH wild type, WHO grade 4
TERT promotor mutation	TERT promoter mutation occurs in ~70% of glioblastoma, IDH wild type and >95% of oligodendroglioma, IDH-mutant and 1p/19q-codeleted Molecular marker of glioblastoma, IDH wild type, WHO grade 4

+7/–10 cytogenetic signature	Molecular marker of glioblastoma, IDH wild type, WHO grade 4
BRAF *V600E* mutation	Rare in adult diffuse gliomas but amenable to pharmacological intervention."[56]

College of American Pathologists

In 2022, The College of American Pathologists in Collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology published guidelines that suggests these following recommendations for molecular biomarker testing for the diagnosis of diffuse gliomas:

- "IDH mutational testing must be performed on all diffuse gliomas (DG) (Strong recommendation)"
- "ATRX status should be assessed in all IDH-mutant DG unless they show 1p/19q codeletion (Strong recommendation)"
- "TP53 status should be assessed in all IDH-mutant DGs unless they show 1p/19q codeletion (Conditional recommendation)"
- "1p/19q codeletion must be assessed in IDH-mutant DGs unless they show ATRX loss or *TP53* mutations (Strong recommendation)"
- "*CDKN2A/B* homozygous deletion testing should be performed on IDH-mutant astrocytomas (Conditional recommendation)"
- "*MGMT* promoter methylation testing should be performed on all glioblastoma (GBM), IDH-wild type (WT) (Strong recommendation)"
- "For IDH-mutant DG, *MGMT* promoter methylation testing may not be necessary (Conditional recommendation)"
- *"TERT* promoter mutation testing may be used to provide further support for the diagnosis of oligodendroglioma and IDH-WT GBM (Conditional recommendation)"
- "For histologic grade 2-3 DGs that are IDH-WT, testing should be performed for whole chromosome 7 gain/whole chromosome 10 loss, *EGFR* amplification, and *TERT* promoter mutation to establish the molecular diagnosis of GBM, IDH-WT, grade IV (Strong recommendation)"
- "H3 K27M testing must be performed in DGs that involve the midline in the appropriate clinical and pathologic setting (Strong recommendation)"
- "H3 G34 testing may be performed in pediatric and young adult patients with IDH-WT DG (Conditional recommendation)"
- "*BRAF* mutation testing (V600) may be performed in DGs that are IDH-WT and H3-WT (Conditional recommendation)"
- "*MYB/MYBL1* AND *FGFR1* testing may be performed in children and young adults with DGs that are histologic grade 2-3 and are IDH-WT and H3-WT (Conditional recommendation)."[57]

VII. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the

Medicare search website: https://www.cms.gov/medicare-coverage-database/search.aspx. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

VIII. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (e.g., glioma), common variants (e.g., R132H, R132C)
81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (e.g., glioma), common variants (e.g., R140W, R172M)
81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (e.g., colon cancer, melanoma), gene analysis, V600 variant(s)
81287	MGMT (O-6-methylguanine-DNA methyltransferase) (e.g., glioblastoma multiforme) promoter methylation analysis
81345	TERT (telomerase reverse transcriptase) (e.g., thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (e.g., promoter region)
81479	Unlisted molecular pathology procedure
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
88374	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each multiplex probe stain procedure
88377	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each multiplex probe stain procedure
0481U	IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (ege.g., central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions) Proprietary test: IDH1, IDH2, and TERT Mutation Analysis, NextGeneration Sequencing, Tumor (IDTRT) Lab/Manufacturer: Mayo Clinic, Laboratory Developed Test

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

IX. Evidence-based Scientific References

1. Louis D, Schiff D, Batchelor T. Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors. Updated September 20, 2024. https://www.uptodate.com/contents/classification-and-pathologic-diagnosis-of-gliomas-glioneuronal-tumors-and-neuronal-tumors
2. Louis D, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta neuropathologica*. Jun 2016;131(6):803-20. doi:10.1007/s00401-016-1545-1
3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology*. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106
4. American Cancer Society. Key Statistics for Brain and Spinal Cord Tumors. 2025;
5. NCCN. NCCN Clinical Practice Guidelines in Oncology; Central Nervous System Cancers v1.2025. National Comprehensive Cancer Network. Updated June 3, 2025. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
6. Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? *Acta neuropathologica*. May 2013;125(5):621-36. doi:10.1007/s00401-013-1106-9
7. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*. Dec 10 2009;462(7274):739-44. doi:10.1038/nature08617
8. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *The New England journal of medicine*. Jun 25 2015;372(26):2499-508. doi:10.1056/NEJMoa1407279
9. Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *The New England journal of medicine*. Jun 25 2015;372(26):2481-98. doi:10.1056/NEJMoa1402121
10. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *The New England journal of medicine*. Nov 9 2000;343(19):1350-4. doi:10.1056/nejm200011093431901
11. Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. *Seminars in cancer biology*. Aug 2018;51:50-58. doi:10.1016/j.semcancer.2017.11.010
12. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *The New England journal of medicine*. Mar 10 2005;352(10):997-1003. doi:10.1056/NEJMoa043331
13. Zhao H, Wang S, Song C, Zha Y, Li L. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. *World journal of surgical oncology*. Oct 12 2016;14(1):261. doi:10.1186/s12957-016-1012-4
14. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. *The Lancet Oncology*. Sep 2012;13(9):916-26. doi:10.1016/s1470-2045(12)70265-6
15. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *The Lancet Oncology*. Jul 2012;13(7):707-15. doi:10.1016/s1470-2045(12)70164-x
16. Wick W, Weller M, van den Bent M, et al. MGMT testing--the challenges for biomarker-based glioma treatment. *Nature reviews Neurology*. Jul 2014;10(7):372-85. doi:10.1038/nrneurol.2014.100

17. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer research*. Oct 15 2006;66(20):9852-61. doi:10.1158/0008-5472.can-06-1796
18. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. Sep 2001;14(9):842-53. doi:10.1038/modpathol.3880400
19. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. *Journal of the National Cancer Institute*. Oct 7 1998;90(19):1473-9. doi:10.1093/jnci/90.19.1473
20. Abedalthagafi M, Phillips JJ, Kim GE, et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. Nov 2013;26(11):1425-32. doi:10.1038/modpathol.2013.90
21. Batchelor T, Louis DN. Molecular pathogenesis of diffuse gliomas. Updated Feburary 14, 2025. https://www.uptodate.com/contents/molecular-pathogenesis-of-diffuse-gliomas
22. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta neuropathologica*. Jan 2015;129(1):133-46. doi:10.1007/s00401-014-1370-3
23. Parikh N, Hilsenbeck S, Creighton CJ, et al. Effects of TP53 Mutational Status on Gene Expression Patterns Across Ten Human Cancer Types. *J Pathol*. Apr 2014;232(5):522-33. doi:10.1002/path.4321
24. Arita H, Narita Y, Takami H, et al. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. *Acta neuropathologica*. Dec 2013;126(6):939-41. doi:10.1007/s00401-013-1203-9
25. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer cell*. Oct 16 2012;22(4):425-37. doi:10.1016/j.ccr.2012.08.024
26. Weinberg DN, Allis CD, Lu C. Oncogenic Mechanisms of Histone H3 Mutations. *Cold Spring Harb Perspect Med*. Jan 03 2017;7(1)doi:10.1101/cshperspect.a026443
27. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*. Jan 29 2012;482(7384):226-31. doi:10.1038/nature10833
28. Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. *Neuro Oncol*. Aug 1 2017;19(8):1127-1134. doi:10.1093/neuonc/now274
29. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature*. Jun 27 2002;417(6892):949-54. doi:10.1038/nature00766
30. Horbinski C. To BRAF or not to BRAF: is that even a question anymore? *Journal of neuropathology and experimental neurology*. Jan 2013;72(1):2-7. doi:10.1097/NEN.0b013e318279f3db
31. Chappe C, Padovani L, Scavarda D, et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. *Brain pathology (Zurich, Switzerland)*. Sep 2013;23(5):574-83. doi:10.1111/bpa.12048
32. Chi AS, Batchelor TT, Yang D, et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. May 10 2013;31(14):e233-6. doi:10.1200/jco.2012.46.0220

Sentara Health Plans

33. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer research*. Nov 1 2008;68(21):8673-7. doi:10.1158/0008-5472.can-08-2097
34. Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. Jul 15 2011;17(14):4790-8. doi:10.1158/1078-0432.ccr-11-0034
35. Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Sep 1 2017;35(25):2934-2941. doi:10.1200/jco.2016.71.8726
36. Malgulwar PB, Nambirajan A, Pathak P, et al. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. *Journal of neuro-oncology*. May 2018;138(1):29-39. doi:10.1007/s11060-018-2767-y
37. NCBI. RELA - RELA proto-oncogene, NF-kB subunit. 2011;
38. Wang L, Liu L, Li H, et al. RELA Fusion in Supratentorial Extraventricular Ependymomas: A Morphologic, Immunohistochemical, and Molecular Study of 43 Cases. *Am J Surg Pathol*. Dec 2019;43(12):1674-1681. doi:10.1097/pas.0000000000001342
39. Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. 2019;doi:10.1038/s41586-019-0882-3
40. Simonelli M, Dipasquale A, Orzan F, et al. Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic? *Crit Rev Oncol Hematol*. Feb 2020;146:102879. doi:10.1016/j.critrevonc.2020.102879
41. Nikiforova MN, Wald AI, Melan MA, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. *Neuro Oncol*. Mar 2016;18(3):379-87. doi:10.1093/neuonc/nov289
42. Zacher A, Kaulich K, Stepanow S, et al. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel. *Brain pathology (Zurich, Switzerland)*. Mar 2017;27(2):146-159. doi:10.1111/bpa.12367
43. Taeeun Kim, Ahwon Lee, Stephan Ahn, Jae Sung Park, Sin Soo Jeun, Lee YS. Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing. *Brain Tumor Research and Treatment*. 2024;doi:10.14791/btrt.2023.0036
44. Ramkissoon SH, Bandopadhayay P, Hwang J, et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. *Neuro Oncol*. Jul 1 2017;19(7):986-996. doi:10.1093/neuonc/now294
45. Ryall S, Krishnatry R, Arnoldo A, et al. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. *Acta neuropathologica communications*. Aug 31 2016;4(1):93. doi:10.1186/s40478-016-0353-0
46. Houdova Megova M, Drabek J, Dwight Z, et al. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. *Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti*. 2017 2017;30(5):361-371. Mutace isocitratdehydrogenazy jsou lepsi prognosticky marker nez metylace promotoru O6-metylguanin-DNA-metyltransferazy u glioblastomu - retrospektivni molekularne geneticka studie gliomu z jednoho centra. doi:10.14735/amko2017361
47. Johnson A, Severson E, Gay L, et al. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. *The oncologist*. Dec 2017;22(12):1478-1490. doi:10.1634/theoncologist.2017-0242

48. Back M, Jayamanne D, Brazier D, et al. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. *Strahlenther Onkol*. Jan 2020;196(1):31-39. Rezidivmuster bei Patienten mit anaplastischem Glioma mit einer IDH1/2-Mutation. doi:10.1007/s00066-019-01467-0
49. Ji J, Kaneva K, Hiemenz MC, et al. Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. *Neuro-Oncology Advances*. 2021;3(1)doi:10.1093/noajnl/vdab037
50. Muralidharan K, Yekula A, Small JL, et al. TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. *Clinical Cancer Research*. 2021;27(1):169-178. doi:10.1158/1078-0432.Ccr-20-3083
51. Cabezas-Camarero S, García-Barberán V, Pérez-Alfayate R, et al. 34P Dynamic changes in plasma PD-L1 in patients with gliomas: Prognostic value and association with IDH status. *Annals of Oncology*. 2021;doi:10.1016/j.annonc.2021.10.050
52. Rios JD, Velummailum R, Bennett J, et al. Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. *BMC Pediatr*. Jan 3 2022;22(1):13. doi:10.1186/s12887-021-03069-1
53. NICE. Brain tumours (primary) and brain metastases in adults. Updated January 29, 2021. https://www.nice.org.uk/guidance/ng99/chapter/Recommendations
54. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. Sep 2014;25 Suppl 3:iii93-101. doi:10.1093/annonc/mdu050
55. Wen PY, Huse JT. 2016 World Health Organization Classification of Central Nervous System Tumors. *Continuum (Minneap Minn)*. Dec 2016;23(6, Neuro-oncology):1531-1547. doi:10.1212/con.0000000000000536
56. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nature Reviews Clinical Oncology*. 2021/03/01 2021;18(3):170-186. doi:10.1038/s41571-020-00447-z
57. Brat DJ, Aldape K, Bridge JA, et al. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. *Arch Pathol Lab Med*. May 1 2022;146(5):547-574. doi:10.5858/arpa.2021-0295-CP

X. Review/Revision History

Effective Date	Summary
02/01/2026	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. Off-Cycle Coding Modification: Added CPT code 0481U (effective date 10/1/2024).
12/01/2024	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. The following edits were made for clarity and consistency: CC1 edited for clarity and consistency. Note was updated to reflect changes to Avalon’s definition of a genetic panel within R2162. Now reads: “Note: For 2 or more gene tests being run on the same platform, please refer to AHS-R2162-Reimbursement Policy.”

12/01/2024	Initial Policy Implementation